-
PublishedJune 10, 2024
Alzheimer’s drug that can slow disease gets backing from FDA advisers
If it wins final approval, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. that's been shown to convincingly slow cognitive decline and memory problems due to Alzheimer's.
-
PublishedMarch 20, 2024
Shadowing Trump’s attacks on mental fitness – his own father’s dementia
Donald Trump’s father’s condition also drove a wedge into his family, which fell into years of lawsuits that alleged in part that Donald Trump sought to take advantage of his father’s dementia to wrest control of the family estate.
-
PublishedFebruary 23, 2024
Air pollution tied to signs of Alzheimer’s in brain tissue, study finds
A study published this week says the association holds for people who are not already genetically predisposed to Alzheimer's.
-
PublishedJanuary 22, 2024
Portland man takes part in drug trial giving new hope in fight against Alzheimer’s disease
Ralph Carmona participated in a clinical research trial for Leqembi, a new Alzheimer's drug that he believes stopped his symptoms from progressing.
-
PublishedFebruary 1, 2023
Sen. Collins spearheads efforts to fund Alzheimer’s research
A bipartisan group of senators is proposing to boost funding for research and prevention through 2035.
-
PublishedSeptember 28, 2022
Gov. Mills launches program to give grants up to $2,000 to family caregivers
The $5.1 million program is for family caregivers of patients with disabilities, such as Alzheimer's and dementia, who are being cared for at home.
-
PublishedSeptember 17, 2022
Photos: 2022 Walk to End Alzheimer’s
Hundreds of people took part in Saturday morning's annual walk in Lewiston.
-
PublishedJuly 13, 2021
Medicare evaluating coverage for $56,000 Alzheimer’s drug
Although pricey drugs are now fairly commonplace, the recent approval of Aduhelm prompted an unusually intense backlash.
-
PublishedJuly 9, 2021
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It's the latest fallout over last month's approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts.
-
PublishedJuly 8, 2021
FDA reverses itself under pressure, moves to limit use of new Alzheimer’s drug
The Food and Drug Administration says the change is intended to address confusion among physicians and patients about who should get Aduhelm, which has faced an intense public backlash since its approval last month.
- 1
- 2
- Next Page →